Spyre Therapeutics, Inc. (SYRE)
85.79
+0.10
(+0.12%)
USD |
NASDAQ |
Sep 28, 16:00
85.85
+0.06
(+0.07%)
After-Hours: 16:43
Spyre Therapeutics Research and Development Expense (TTM) : 215.80M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 215.80M |
| March 31, 2026 | 190.44M |
| December 31, 2025 | 171.65M |
| September 30, 2025 | 177.50M |
| June 30, 2025 | 176.99M |
| March 31, 2025 | 169.48M |
| December 31, 2024 | 162.79M |
| September 30, 2024 | 145.99M |
| June 30, 2024 | 125.91M |
| March 31, 2024 | 110.66M |
| December 31, 2023 | 89.50M |
| September 30, 2023 | 70.07M |
| June 30, 2023 | 57.39M |
| March 31, 2023 | 55.38M |
| December 31, 2022 | 58.58M |
| September 30, 2022 | 61.11M |
| June 30, 2022 | 63.99M |
| March 31, 2022 | 62.19M |
| December 31, 2021 | 57.07M |
| September 30, 2021 | 56.04M |
| June 30, 2021 | 53.64M |
| March 31, 2021 | 56.93M |
| Date | Value |
|---|---|
| December 31, 2020 | 59.64M |
| September 30, 2020 | 61.45M |
| June 30, 2020 | 66.84M |
| March 31, 2020 | 64.77M |
| December 31, 2019 | 64.60M |
| September 30, 2019 | 58.83M |
| June 30, 2019 | 49.92M |
| March 31, 2019 | 44.24M |
| December 31, 2018 | 36.72M |
| September 30, 2018 | 30.71M |
| June 30, 2018 | 28.02M |
| March 31, 2018 | 24.74M |
| December 31, 2017 | 22.81M |
| September 30, 2017 | 21.76M |
| June 30, 2017 | 20.91M |
| March 31, 2017 | 19.50M |
| December 31, 2016 | 18.14M |
| September 30, 2016 | 17.37M |
| June 30, 2016 | 15.11M |
| March 31, 2016 | 13.43M |
| December 31, 2015 | 11.45M |
| September 30, 2015 | 10.04M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| AbbVie, Inc. | 9.714B |
| Incyte Corp. | 2.098B |
| SELLAS Life Sciences Group, Inc. | 20.35M |
| Relay Therapeutics, Inc. | 270.72M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |